Market Overview

St. Jude Reports Purchase, CE Mark Approval of World's First Leadless Pacemaker

Related STJ
Markets Up As Russia Seeks To End Military Activity Near Ukraine
Sotheby's Slips On Downbeat Earnings; NVIDIA Shares Surge

St. Jude Medical, Inc. (NYSE: STJ), a global medical device company, today announced the completion of its acquisition of Nanostim, Inc., a privately-owned developer of miniaturized, leadless pacemakers. The acquisition adds the world's first and only leadless pacemaker to the St. Jude Medical product portfolio and culminates a two-year partnership between the two companies during which St. Jude Medical invested in and collaborated with Nanostim throughout its product development and commercialization initiatives.

Unlike conventional pacemakers that require a more invasive surgery, the Nanostimâ„¢ leadless pacemaker is designed to be implanted directly into the heart via a minimally invasive procedure. The device is delivered using a steerable catheter through the femoral vein, eliminating the need to surgically create a pocket for the pacemaker and insulated wires (called leads) that have historically been recognized as the most vulnerable component of pacing systems. The Nanostim leadless pacemaker recently received CE Mark approval and will be available soon in select European markets. It also recently received U.S. Food and Drug Administration (FDA) conditional approval for its Investigational Device Exemption (IDE) application and pivotal clinical trial protocol to begin evaluating Nanostim leadless technology in the U.S.

Posted-In: News FDA

 

Most Popular

Related Articles (STJ)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters